BioSpace News Archive

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and fibrosis, reports financial results for the three months ended March 31, 2021.

– Safety and efficacy study for macimorelin initiated as agreed with U . S . FDA and the European Medicines Agency (“EMA”) in the Company’s Pediatric Investigation Plan (“PIP”) – Patient enrollment on track to start this quarter – Planned completion of pivotal Phase 3 study expected in Q3 2022

Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that Sean Browne, Chief Executive Officer, will present at the Canaccord Musculoskeltal Conference on Thursday, May 20, 2021, at 3:00 PM Eastern Time.

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at two upcoming virtual investor conferences: Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 at 11:35am ET Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 1:30pm ET

Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces the filing of its SEC Form 10-Q (quarterly report), for the quarter ended March 31, 2021.

BioCardia ® , Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular and pulmonary cell based therapies, today reported financial results for the first quarter of 2021 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2021 with the Securities and Exchange Commission on May 13, 2021.

ARS Pharmaceuticals, Inc., a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions potentially leading to anaphylaxis, announced the appointment of biotech leader and visionary Brent Saunders to its Board of Directors.

InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that management will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on Wednesday, May 26.

DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy, announced the appointment of Hongjun “Harry” Yang, Ph.D., former Executive Personalized Healthcare Strategy Leader at AstraZeneca, as Senior Vice President of Companion Diagnostics at DiaCarta.

Pear Therapeutics, Inc. today announced that Chris Guiffre, J.D., M.B.A., Chief Financial Officer and Chief Operating Officer, will participate in a panel discussion at the Citi Private Company Digital Health Conference. The virtual panel discussion, “The Digitization of Therapies,” will take place on Thursday, May 20 at 2:00 p.m. ET. Pear Therapeutics is a privately held, prescription digital therapeuti